Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
What is the purpose of this trial?
This phase II trial studies how well daratumumab, pomalidomide, and dexamethasone work in treating patients with multiple myeloma that has come back (relapsed). Immunotherapy with daratumumab may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as pomalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab with dexamethasone and pomalidomide may work bettering in treating patient compared to dexamethasone and pomalidomide alone.
- Trial withAmgen, Inc.
- Start Date01/13/2021
- End Date03/31/2024
- Last Updated07/15/2021
- Study HIC#2000026003